• Home
  • >
  • Lincoln Pharmaceuticals Ltd Financials
https://storage.googleapis.com/assets.cdp.blinkx.in/Blinkx_Website/icons/lincoln-pharmaceuticals-ltd.png Logo

Lincoln Pharmaceuticals Ltd Financial Statement

Lincoln Pharmaceuticals Ltd Income Statement
Quarterly
Annual

*All values are in Rs. Cr

(Rs. CR)Mar 2024Dec 2023Sep 2023
Revenue149.51157.47164.68
Operating Expense124.11116.79124.84
Net Profit18.628.0427.65
Net Profit Margin12.4417.8116.79
Earning Per Share9.281413.81
EBIDTA25.938.2139.23
Effective Tax Rate16.1817.7221.61

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

Lincoln Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Total Revenue Annual510.31472.12424.19
Operating Expenses Annual421.11376.64337.01
Operating Profit Annual111.68105.4892.84
Interest Annual2.031.451.56
Depreciation9.057.957.4
Net Profit Annual72.969.3662.25
Tax Annual27.5826.5821.47

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

Lincoln Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Cash Flow at the Beginning6.9311.4412.14
Cash Flow from Operations39.2676.1369.27
Cash Flow from Investing-36.64-78.08-64.23
Cash Flow from Financing-4.5-2.56-5.75
Cash Flow at the End5.056.9311.44

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

Lincoln Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
PBDIT Margin (%)21.8822.3421.89
PBIT Margin (%)20.0920.6320.1
PBT Margin (%)10.196.47.17
Net PROFIT Margin (%)14.2914.6914.72
Return On Networth / Equity (%)15.5917.3618.32
Return On Networth /Employed(%)21.6124.0324.6
Return On Assets (%)15.4317.0417.96
Total Debt / Equity(X)TBATBA0.01
Asset Turnover Ratio (%)1.081.161.22

Particulars

PBDIT Margin (%)

PBIT Margin (%)

PBT Margin (%)

Net PROFIT Margin (%)

Return On Networth / Equity (%)

Return On Networth / Employed(%)

Return On Assets (%)

Total Debt / Equity(X)

Asset Turnover Ratio (%)

Lincoln Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Fixed Assets Annual150.53131.88110.64
Total Current Assets Annual367.21352.85308.75
Non Current Assets Annual220.21181.51143.61
Total Shareholders Funds Annual502.47432.88366.39
Total Assets Annual587.42534.36452.36

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

Lincoln Pharmaceuticals Ltd Earning Calls
Mar 2024
EPS beaten by -0.11 %

Open Demat Account

50years
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

PE Ratio

Get Your FAQs Right

As of May 20, 2024, Lincoln Pharmaceuticals Ltd has a market capitalization of 1,172.54 Cr. Value Research classifies it as a Small-Cap company.

Yes, Lincoln Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.00.

In FY 2023, Lincoln Pharmaceuticals Ltd recorded a total revenue of approximately 580.55 Cr marking a significant milestone in the company's financial performance.

Lincoln Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.3% and 0.1% annually, respectively..

Lincoln Pharmaceuticals Ltd's current PE ratio is 12.57.

Lincoln Pharmaceuticals Ltd's ROCE averaged 21.0% from the FY ending March 2022 to 2024, with a median of 20.7%. It peaked at 22.2% in March 2022, reflecting strong capital efficiency over the period..

Lincoln Pharmaceuticals Ltd's latest EBIT is Rs. 123.7 Cr, surpassing the average EBIT of Rs. 107.87 Cr over the 5 years..